Application of cationic liposomes for delivery of nucleic acids

Asian Journal of Pharmaceutical Sciences

Volumn 8, Issue 2, 2013, Pages 72-80

  Shim, Gayong ^a   Kim, Mi Gyeong ^a   Park, Joo Yeon ^a   Oh, Yu Kyoung ^a  

^a Seoul National University   (South Korea)

Author keywords

Cationic lipid; Delivery; Liposomes; Nucleic acid therapeutics; Plasmid DNA; siRNA

Indexed keywords

CATIONIC LIPOSOME; LIPOPLEX; LIPOSOME; MICRORNA; NANOPARTICLE; NUCLEIC ACID; OLIGONUCLEOTIDE; PLASMID DNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; 1,2 DILINOLEYLOXY 3 DIMETHYLAMINOPROPANE; 1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; 1,2 DIOLEOYL SN GLYCERO 3 PHOSPHOETHANOLAMINE; 3BETA [N (N',N' DIMETHYLAMINOETHANE)CARBAMOYL]CHOLESTEROL; AMIDE; ANTISENSE OLIGODEOXYNUCLEOTIDE; CHOLESTEROL; DIOLEOYLPHOSPHATIDYLCHOLINE; DIOSGENIN; DNA; GLYCEROPHOSPHOLIPID; IMIDAZOLE DERIVATIVE; LIPOFECTAMINE; MACROGOL; MICRORNA 7; N LAUROYLSARCOSINE; N [1 (2,3 DIOLEYLOXY)PROPYL] N,N,N TRIMETHYLAMMONIUM CHLORIDE; N',N' DIOCTADECYL N 4,8 DIAZA 10 AMINODECANOYLGLYCINE AMIDE; O,O' DITETRADECANOYL N (ALPHA TRIMETHYLAMMONIOACETYL)DIETHANOLAMINE CHLORIDE; PHOSPHOETHANOLAMINE; PROPYLAMINE; QUATERNARY AMMONIUM DERIVATIVE; SARCOSINE; UNINDEXED DRUG;

ARTICLE; DRUG DELIVERY SYSTEM; HUMAN; LIPID COMPOSITION; NONHUMAN; ANTINEOPLASTIC ACTIVITY; BIOMEDICAL ENGINEERING; CELL MEMBRANE POTENTIAL; CHEMICAL MODIFICATION; COMPLEX FORMATION; DRUG CONJUGATION; GENE SILENCING; GENETIC TRANSFECTION; HYDROPHOBICITY; LIPOSOMAL DELIVERY; PINOCYTOSIS; RNA INTERFERENCE; STRUCTURE ACTIVITY RELATION;

EID: 84881367153     PISSN: 18180876     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajps.2013.07.009     Document Type: Article

References (60)

1. Elsabahy M, Nazarali A, M. Foldvari M. Non-viral nucleic acid delivery: key challenges and future directions. Curr Drug Deliv. 2011, 8:235-244.
2. Gao Y, Liu XL, Li XR. Research progress on siRNA delivery with nonviral carriers. Int J Nanomedicine. 2011, 6:1017-1025.
3. Guo J, Fisher KA, Darcy R, et al. Therapeutic targeting in the silent era: advances in non-viral siRNA delivery. Mol Biosyst. 2010, 6:1143-1161.
4. Giacca M, Zacchigna S. Virus-mediated gene delivery for human gene therapy. J Control Release. 2012, 161:377-388.
5. Thacker EE, Timares L, Matthews QL. Strategies to overcome host immunity to adenovirus vectors in vaccine development. Expert Rev Vaccines. 2009, 8(6):761-77.
6. Ojea-Jimenez I, Tort O, Lorenzo J, et al. Engineered nonviral nanocarriers for intracellular gene delivery applications. Biomed Mater. 2012, 7:054106.
7. Yuan X, Naguib S, Wu Z. Recent advances of siRNA delivery by nanoparticles. Expert Opin Drug Deliv. 2011, 8:521-536.
8. Tan SJ, Kiatwuthinon P, Roh YH, et al. Engineering Nanocarriers for siRNA Delivery. Small. 2011, 7(7):841-56.
9. Jeong JH, Park TG, Kim SH. Self-assembled and nanostructured siRNA delivery systems. Pharm Res. 2011, 28:2072-2085.
10. Felgner PL, Gadek TR, Holm M, et al. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci U S A. 1987, 84:7413-7417.
11. Akinc A, Zumbuehl A, Goldberg M, et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol. 2008, 26:561-569.
12. Mevel M, Kamaly N, Carmona S, et al. DODAG; a versatile new cationic lipid that mediates efficient delivery of plasmid DNA and siRNA. J Control Release. 2010, 143:222-232.
13. Semple SC, Akinc A, Chen J, et al. Rational design of cationic lipids for siRNA delivery. Nat Biotechnol. 2010, 28:172-176.
14. Huang QD, Zhong GX, Zhang Y, et al. Cyclen-based cationic lipids for highly efficient gene delivery towards tumor cells. PLoS One. 2011, 6(8):e23134.
15. Chen J, Yu Z, Chen H, et al. Transfection efficiency and intracellular fate of polycation liposomes combined with protamine. Biomaterials. 2011, 32:1412-1418.
16. Mosca M, Ceglie A, Ambrosone L. Effect of membrane composition on lipid oxidation in liposomes. Chem Phys Lipids. 2011, 164(2):158-165.
17. Dabkowska AP, Barlow DJ, Campbell RA, et al. Effect of helper lipids on the interaction of DNA with cationic lipid monolayers studied by specular neutron reflection. Biomacromolecules. 2012, 13:2391-2401.
18. Kurosaki T, Kitahara T, Teshima M, et al. Exploitation of De Novo helper-lipids for effective gene delivery. J Pharm Pharm Sci. 2008,11:56-67.
19. Zhang Y, Li H, Sun J, et al. DC-Chol/DOPE cationic liposomes: a comparative study of the influence factors on plasmid plasmid DNA and siRNA gene delivery. Int J Pharm. 2010, 390:198-207.
20. Marchini C, Pozzi D, Montani M, et al. Tailoring lipoplex composition to the lipid composition of plasma membrane: a Trojan horse for cell entry? Langmuir. 2010, 26:13867-13873.
21. Charoensit P, Kawakami S, Higuchi Y, et al. Enhanced growth inhibition of metastatic lung tumors by intravenous injection of ATRA-cationic liposome/IL-12 plasmid DNA complexes in mice. Cancer Gene Ther. 2010, 17:512-522.
22. Rai K, Takigawa N, Ito S, et al. Liposomal delivery of MicroRNA-7-expressing plasmid overcomes epidermal growth factor receptor tyrosine kinase inhibitor-resistance in lung cancer cells. Mol Cancer Ther. 2011, 10:1720-1727.
23. Zhang C, Newsome JT, Mewani R, et al. Systemic delivery and pre-clinical evaluation of nanoparticles containing antisense oligonucleotides and siRNAs. Methods Mol Biol. 2009, 480:65-83.
24. Koh CG, Zhang X, Liu S, et al. Delivery of antisense oligodeoxyribonucleotide lipopolyplex nanoparticles assembled by microfluidic hydrodynamic focusing. J Control Release. 2010, 141:62-69.
25. Kim ST, Lee KM, Park HJ, et al. Topical delivery of interleukin-13 antisense oligonucleotides with cationic elastic liposome for the treatment of atopic dermatitis. J Gene Med. 2009, 11:26-37.
26. Zhou S, Kawakami S, Yamashita F, et al. Intranasal administration of CpG DNA lipoplex prevents pulmonary metastasis in mice. Cancer Lett. 2010, 287:75-81.
27. Zhou S, Kawakami S, Higuchi Y, et al. The involvement of NK cell activation following intranasal administration of CpG DNA lipoplex in the prevention of pulmonary metastasis and peritoneal dissemination in mice. Clin Exp Metastasis. 2012, 29:63-70.
28. Puangpetch A, Anderson R, Huang YY, et al. Cationic liposomes extend the immunostimulatory effect of CpG oligodeoxynucleotide against Burkholderia pseudomallei infection in BALB/c mice. Clin Vaccine Immunol. 2012, 19:675-683.
29. Akao Y, Nakagawa Y, Hirata I, et al. Role of anti-oncomirs miR-143 and -145 in human colorectal tumors. Cancer Gene Ther. 2010, 17:398-408.
30. Barichello JM, Kizuki S, Tagami T, et al. Agitation during lipoplex formation harmonizes the interaction of siRNA to cationic liposomes. Int J Pharm. 2012, 430:359-365.
31. Basha G, Novobrantseva TI, Rosin N, et al. Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells. Mol Ther. 2011, 19:2186-2200.
32. Liu X, Madhankumar AB, Slagle-Webb B, et al. Heavy chain ferritin siRNA delivered by cationic liposomes increases sensitivity of cancer cells to chemotherapeutic agents. Cancer Res. 2011, 71:2240-2249.
33. Tagami T, Suzuki T, Matsunaga M, et al. Anti-angiogenic therapy via cationic liposome-mediated systemic siRNA delivery. Int J Pharm. 2012, 422:280-289.
34. Wu Y, Crawford M, Yu B, et al. MicroRNA delivery by cationic lipoplexes for lung cancer therapy. Mol Pharm. 2011, 8:1381-1389.
35. Pramanik D, Campbell NR, Karikari C, et al. Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice. Mol Cancer Ther. 2011, 10:1470-1480.
36. Briane D, Slimani H, Tagounits A, et al. Inhibition of VEGF expression in A431 and MDA-MB-231 tumour cells by cationic lipid-mediated siRNA delivery. J Drug Target. 2012, 20:347-354.
37. Maslov MA, Kabilova TO, Petukhov IA, et al. Novel cholesterol spermine conjugates provide efficient cellular delivery of plasmid DNA and small interfering RNA. J Control Release. 2012, 160:182-193.
38. Kim HK, Davaa E, Myung CS, et al. Enhanced siRNA delivery using cationic liposomes with new polyarginine-conjugated PEG-lipid. Int J Pharm. 2010, 392:141-147.
39. Chen Y, Bathula SR, Yang Q, et al. Targeted nanoparticles deliver siRNA to melanoma. J Invest Dermatol. 2010, 130:2790-2798.
40. Adami RC, Seth S, Harvie P, et al. An amino acid-based amphoteric liposomal delivery system for systemic administration of siRNA. Mol Ther. 2011, 19:1141-1151.
41. Li L, Song H, Luo K, et al. Gene transfer efficacies of serum-resistant amino acids-based cationic lipids: dependence on headgroup, lipoplex stability and cellular uptake. Int J Pharm. 2011, 408:183-190.
42. Markov OO, Mironova NL, Maslov MA, et al. Novel cationic liposomes provide highly efficient delivery of DNA and RNA into dendritic cell progenitors and their immature offsets. J Control Release. 2012, 160:200-210.
43. Li L, Zahner D, Su Y, et al. A biomimetic lipid library for gene delivery through thiol-yne click chemistry. Biomaterials. 2012, 33:8160-8166.
44. Schlegel A, Largeau C, Bigey P, et al. Anionic polymers for decreased toxicity and enhanced in vivo delivery of siRNA complexed with cationic liposomes. J Control Release. 2011, 152:393-401.
45. Jiang J, Yang SJ, Wang JC, et al. Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin. Eur J Pharm Biopharm. 2010, 76:170-178.
46. Kibria G, Hatakeyama H, Ohga N, et al. Dual-ligand modification of PEGylated liposomes shows better cell selectivity and efficient gene delivery. J Control Release. 2011, 153:141-148.
47. Duarte S, Faneca H, Lima MC. Folate-associated lipoplexes mediate efficient gene delivery and potent antitumoral activity in vitro and in vivo. Int J Pharm. 2012, 423:365-377.
48. Li H, Piao L, Yu B, et al. Delivery of calf thymus DNA to tumor by folate receptor targeted cationic liposomes. Biomaterials. 2011, 32:6614-6620.
49. O'Brian CA, Ward NE, Vogel VG. Inhibition of protein kinase C by the 12-O-tetradecanoylphorbol-13-acetate antagonist glycyrrhetic acid. Cancer Lett. 1990, 49: 9-12.
50. He ZY, Zheng X, Wu XH, et al. Development of glycyrrhetinic acid-modified stealth cationic liposomes for gene delivery. Int J Pharm. 2010, 397:147-154.
51. Dinh TD, Higuchi Y, Kawakami S, et al. Evaluation of osteoclastogenesis via NFkappaB decoy/mannosylated cationic liposome-mediated inhibition of pro-inflammatory cytokine production from primary cultured macrophages. Pharm Res. 2011, 28:742-751.
52. Wijagkanalan W, Kawakami S, Higuchi Y, et al. Intratracheally instilled mannosylated cationic liposome/NFkappaB decoy complexes for effective prevention of LPS-induced lung inflammation. J Control Release. 2011, 149:42-50.
53. Bauman JA, Li SD, Yang A, et al. Anti-tumor activity of splice-switching oligonucleotides. Nucleic Acids Res. 2010, 38(22):8348-8356.
54. Kim TH, Yu GS, Choi H, et al. Preparation of dexamethasone-based cationic liposome and its application to gene delivery in vitro. J Nanosci Nanotechnol. 2011, 11:1799-1802.
55. Kang SH, Cho HJ, Shim G, et al. Cationic liposomal co-delivery of small interfering RNA and a MEK inhibitor for enhanced anticancer efficacy. Pharm Res. 2011, 28:3069-3078.
56. Shim G, Han SE, Yu YH, et al. Trilysinoyl oleylamide-based cationic liposomes for systemic co-delivery of siRNA and an anticancer drug. J Control Release. 2011, 155:60-66.
57. Xiao W, Chen X, Yang L, et al. Co-delivery of doxorubicin and plasmid by a novel FGFR-mediated cationic liposome. Int J Pharm. 2010, 393:119-126.
58. Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol. 2010, 7(11):653-64.
59. Guo P, Coban O, Snead NM, et al. Engineering RNA for targeted siRNA delivery and medical application. Adv Drug Deliv Rev. 2010, 62:650-666.
60. Burnett JC, Rossi JJ, Tiemann K. Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol J. 2011, 6:1130-1146.